PremiumThe FlyRoche granted FDA BDD for VENTANA TROP2 RxDx Device Roche price target lowered to CHF 250 from CHF 265 at Deutsche Bank Roche downgraded to Hold from Buy at HSBC PremiumRatingsRoche Holding AG: Mixed Q1’25 Results and Strategic U.S. Investments Justify Hold Rating Roche sees FY25 core EPS growing in high single digit range Roche reports Q1 group sales CHF 15.4B vs. CHF 14.4B last year PremiumThe FlyTempest Therapeutics downgraded at Scotiabank as amezalpat finds no suitors Trump plans to announce ‘major’ tariff on pharmaceutical imports, Reuters says Roche price target raised to CHF 312 from CHF 305 at Morgan Stanley 
